Bifidobacterium longum as a delivery system of TRAIL and endostatin cooperates with chemotherapeutic drugs to inhibit hypoxic tumor growth

Cancer Gene Therapy

Volumn 16, Issue 8, 2009, Pages 655-663

  Hu, B ^a   Kou, L ^a   Li, C ^a   Zhu, L P ^a   Fan, Y R ^b   Wu, Z W ^a   Wang, J J ^a   Xu, G X ^a,c  

^a NANJING UNIVERSITY   (China)

^b NANJING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c Gene Pharmaceutical Engineering and Technology   (China)

Author keywords

Bifidobacterium longum; Endostatin; Gene therapy; Interactions; Selective location; Synergistic; TRAIL

Indexed keywords

CARBOHYDRATE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ENDOSTATIN; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTERIAL GROWTH; BIFIDOBACTERIUM LONGUM; CANCER GENE THERAPY; CONTROLLED STUDY; DRUG POTENTIATION; ELECTROPORATION; EXPRESSION VECTOR; FERMENTATION; GENE DELIVERY SYSTEM; GENETIC TRANSFECTION; GROWTH CURVE; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN DOMAIN; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIFIDOBACTERIUM; BONE NEOPLASMS; COMBINED MODALITY THERAPY; DOXORUBICIN; DRUG DELIVERY SYSTEMS; ENDOSTATINS; MALE; MICE; OSTEOSARCOMA; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; XENOGRAFT MODEL ANTITUMOR ASSAYS;

BIFIDOBACTERIUM LONGUM; MUS;

EID: 67651120191     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2009.7     Document Type: Article

References (49)

1. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Aahkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor family. J Biol Chem 1996; 271: 12687-12690.
2. Wiley SR, Schooley K, Smoolak PJ, Din WS, Huang CP, Nicholl JK et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3: 673-682.
3. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997; 277: 818-821.
4. Wu GS, Burns TF, McDonald III ER, Jiang W, Meng R, Krantz ID et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 1997; 17: 141-143.
5. Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kB pathway. Immunity 1997; 7: 821-830.
6. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a new death domaincontaining receptors for TRAIL. Science 1997; 277: 815-818.
7. Screaton GR, Mongkolsapaya J, Xu XN, Cowper AE, McMichael AJ, Bell JI. TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL. Curr Biol 1997; 7: 693-696.
8. Ashkenazi A. Targeting death and decoy receptors of the tumour necrosis factor superfamily. Nat Rev Cancer 2002; 2: 420-430.
9. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155-162.
10. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M et al. Tumoricidal activity of tumor necrosis factorrelated apoptosis-inducing ligand in vivo. Nat Med 1999; 5: 157-163.
11. Roth W, Isenmann S, Naumann U, Kügler S, Bähr M, Dichgans J et al. Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. Biochem Biophys Res Commun 1999; 265: 479-483.
12. Gliniak B, Le T. Tumor necrosis factor-related apoptosisinducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. Cancer Res 1999; 59: 6153-6158.
13. Nimmanapalli R, Porosnicu M, Nguyen D, Worthington E, O'Bryan E, Perkins C et al. Cotreatment with STI-571 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL or apo-2L)-induced apoptosis of Bcr-Ablpositive human acute leukemia cells. Clin Cancer Res 2001; 7: 350-357.
14. Naka T, Sugamura K, Hylander BL, Widmer MB, Rustum YM, Repasky EA. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. Cancer Res 2002; 62: 5800-5806.
15. Marteau PR, de Vrese M, Cellier CJ, Shrezenmeir J. Protection from gastrointestinal diseases with the use of probiotics. Am J Clin Nutr 2001; 73: 430S-436S.
16. Ito M, Sawada H, Ohishi K, Yoshida Y, Yokoi W, Watanabe T et al. Suppressive effects of Bifidobacteria on lipid peroxidation in the colonic mucosa of iron-overloaded mice. J Dairy Sci 2001; 84: 1583-1589.
17. Yasui H, Ohwaki M. Enhancement of immune response in Peyer's patch cells cultured with Bifidobacterium breve. J Dairy Sci 1991; 74: 1187-1195.
18. Kimura NT, Taniguchi S, Aoki K, Baba T. Selective localization and growth of Bifidobacterium bifidum in mouse tumors following intravenous administration. Cancer Res 1980; 40: 2061-2068.
19. Yazawa K, Fujimori M, Amano J, Kano Y, Taniguchi S. Bifidobacterium longum as a delivery system for cancer gene therapy: selective location and growth in hypoxic tumors. Cancer Gene Ther 2000; 7: 269-274.
20. Singh J, Rivenson A, Tomita M, Shimamura S, Ishibashi N, Reddy BS. Bifidobacterium longum, a lactic acid-producing intestinal bacterium inhibits colon cancer and modulates the intermediate biomarkers of colon carcinogenesis. Carcinogenesis 1997; 18: 833-841.
21. Fujimori M, Amano J, Taniguchi S. The genus Bifidobacterium for cancer gene therapy. Curr Opin Drug Discov Devel 2002; 5: 200-203.
22. Pawelek J, Low K, Bermudes D. Bacteria as tumourtargeting vectors. Lancet Oncol 2003; 4: 548-556.
23. Rossi M, Brigidi P, Matteuzzi D. Improved cloning vectors for Bifidobacterium spp. Lett Appl Microbiol 1998; 26: 101-104.
24. Rossi M, Brigidi P, Gonzalez Vara y Rodriguez A, Matteuzzi D. Characterization of the plasmid pMB1 from Bifidobacterium longum and its use for shuttle vector construction. Res Microbiol 1996; 147: 133-143.
25. Yazawa K, Fujimori M, Nakamura T, Sasaki T, Amano J, Kano Y et al. Bifidobacterium longum as a delivery system for gene therapy of chemically induced rat mammary tumors. Breast Cancer Res Treat 2001; 66: 165-170.
26. Nakamura T, Sasaki T, Fujimori M, Yazawa K, Kano Y, Amano J et al. Cloned cytosine deaminase gene expression of Bifidobacterium longum and application to enzyme/pro-drug therapy of hypoxic solid tumors. Biosci Biotechnol Biochem 2002; 66: 2362-2366.
27. Li X, Fu GF, Fan YR, Liu WH, Liu XJ, Wang JJ et al. Bifidobacterium adolescentis as a delivery system of endostatin for cancer gene therapy: selective inhibitor of angiogenesis and hypoxic tumor growth. Cancer Gene Ther 2003; 10: 105-111.
28. Fu GF, Li X, Hou YY, Fan YR, Liu WH, Xu GX. Bifidobacterium longum as an oral delivery system of endostatin for gene therapy on solid liver cancer. Cancer Gene Ther 2005; 12: 133-140.
29. Yi C, Huang Y, Guo ZY, Wang SR. Antitumor effect of cytosine deaminase/5-fluorocytosine suicide gene therapy system mediated by Bifidobacterium infantis on melanoma. Acta Pharmacol Sin 2005; 26: 629-634.
30. Xu YF, Zhu LP, Hu B, Fu GF, Zhang HY, Wang JJ et al. A new expressing plasmid in Bifidobacterium Longum as a delivery system of endostatin for cancer gene therapy. Cancer Gene Ther 2007; 14: 151-157.
31. Park MS, Kwon B, Shim JJ, Huh CS, Ji GE. Heterologous expression of cholesterol oxidase in Bifidobacterium longum under the control of 16S rRNA gene promoter of bifidobacteria. Biotechnol Lett 2008; 30: 165-172.
32. Reyes Escogido ML, De Leon Rodriguez A, Barba de la Rosa AP. A novel binary expression vector for production of human IL-10 in Escherichia coli and Bifidobacterium longum. Biotechnol Lett 2007; 29: 1249-1253.
33. Guglielmetti S, Ciranna A, Mora D, Parini C, Karp M. Construction, characterization and exemplificative application of bioluminescent Bifidobacterium longum biovar longum. Int J Food Microbiol 2008; 124: 285-290.
34. Rossi M, Brigidi P, Matteuzzi D. An efficient transformation system for Bifidobacterium spp. Lett Appl Microbiol 1997; 24: 33-36.
35. Park MS, Lee KH, Ji GE. Isolation and characterization of two plasmids from Bifidobacterium longum. Lett Appl Microbiol 1997; 25: 5-7.
36. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390: 404-407.
37. Yi C, Huang Y, Guo Z, Wang S. Construction of Bifidobacterium Infantis/CD targeting gene therapy system. The Chinese-German Journal of Clinical Oncology 2005; 4: 244-247.
38. Zhu L, L i W, D ong X. Species identification of genus Bifidobacterium based on partial HSP60 gene sequences and proposal of Bifidobacterium thermacidophilum subsp. porcinum subsp. nov. Int J Syst Evol Microbiol 2003; 53: 1619-1623.
39. Singh TR, Shankar S, Chen X, Asim M, Srivastava RK. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on inhibition of breast carcinoma in vivo. Cancer Res 2003; 63: 5390-5400.
40. Jin H, Yang R, Fong S, Totpal K, Lawrence D, Zheng Z et al. Apo2 ligand/tumor necrosis factor related apoptosisinducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Cancer Res 2004; 64: 4900-4905.
41. Son YG, Kim EH, Kim JY, Kim SU, Kwon TK, Yoon AR et al. Silibinin sensitizes human glioma cells to TRAILmediated apoptosis via DR5 pp-regulation and downregulation of c-FLIP and survivin. Cancer Res 2007; 67: 8274-8284.
42. Baritaki S, H uerta-Yepez S, S akai T, Spandidos DA, Bonavida B. Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1. Mol Cancer Ther 2007; 6: 1387-1399.
43. Wen J, Ramadevi N, Nguyen D, Perkins C, Worthington E, Bhalla K. Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells. Blood 2000; 96: 3900-3906.
44. Gibson SB, Oyer R, Spalding AC, Anderson SM, Johnson GL. Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL. Mol Cell Biol 2000; 20: 205-212.
45. Matsui T, So wa Y, Yo shida T, Murata H, Ho rinaka M, Wakada M et al. Sulforaphane enhances TRAIL-induced apoptosis through the induction of DR5 expression in human osteosarcoma cells. Carcinogenesis 2006; 27: 1768-1777.
46. Villunger A, Michalak EM, Coultas L, Müllauer F, Böck G, Ausserlechner MJ et al. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 2003; 302: 1036-1038.
47. Siervo-Sassi RR, Marrangoni AM, Feng X, Naoumova N, Winans M, Edwards RP et al. Physiological and molecular effects of Apo2L/TRAIL and cisplatin in ovarian carcinoma cell lines. Cancer Lett 2003; 190: 61-72.
48. Chen X, Kandasamy K, Srivastava RK. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kB in tumor necrosis factor-related apoptosis inducing ligand signaling. Cancer Res 2003; 63: 1059-1066.
49. Meurette O, Fontaine A, Rebillard A, Le Moigne G, Lamy T, Lagadic-gossmann D et al. Cytotoxicity of TRAIL/anticancer drug combinations in human normal cells. Ann NY Acad Sci 2006; 1090: 209-216.